OABI

In the past six months, OmniAb's stock has been impacted by several events, including Q4 2025, Q1 2026, and Q2 2026 earnings reports, and participation in various investor conferences such as Leerink Partners, H.C. Wainwright, Benchmark, Jefferies, and Nasdaq/LD Micro Summit Series. A significant positive event was the global collaboration and license agreement for an ion channel program with Eli Lilly & Company announced on August 17, 2026, which also led to raised 2026 financial guidance. Whitefort Capital group reported a 7.1% ownership stake on August 14, 2026, and an Investor & Analyst Day is scheduled for October 6, 2026. Over the past 12 months, OmniAb's stock price has gained 184.5%, trading between $1.30 and $5.43.